Reported Saturday, Merck And Eisai's Phase 3 LEAP-012 Trial OF KEYTRUDA-LENVIMA Combo Shows 34% Reduction In Progression For Advanced Liver Cancer
Author: Benzinga Newsdesk | September 16, 2024 02:36am
In the Phase 3 LEAP-012 trial, KEYTRUDA plus LENVIMA in combination with TACE reduced the risk of disease progression or death by 34% compared to TACE alone
Late-breaking first interim analysis results are being presented during a Presidential Symposium session at the European Society for Medical Oncology Congress 2024